PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-11.35%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-38.74%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-444.62%
Negative EBIT growth while CSIQ is at 12.45%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-279.01%
Negative operating income growth while CSIQ is at 7.25%. Joel Greenblatt would press for urgent turnaround measures.
-817.67%
Negative net income growth while CSIQ stands at 7.55%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-825.00%
Negative EPS growth while CSIQ is at 7.44%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-825.00%
Negative diluted EPS growth while CSIQ is at 5.41%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.17%
Share count expansion well above CSIQ's 0.02%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-0.56%
Reduced diluted shares while CSIQ is at 0.16%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-1062.88%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-493.32%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-52.73%
Negative 10Y revenue/share CAGR while CSIQ stands at 333.09%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-9.62%
Negative 5Y CAGR while CSIQ stands at 8.36%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-5.06%
Negative 3Y CAGR while CSIQ stands at 89.64%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-155.15%
Negative 10Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
53.48%
OCF/share CAGR of 53.48% while CSIQ is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
27.20%
3Y OCF/share CAGR of 27.20% while CSIQ is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
31.95%
Below 50% of CSIQ's 1383.44%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
62.15%
5Y net income/share CAGR at 75-90% of CSIQ's 75.15%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
-3593.20%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-63.50%
Negative equity/share CAGR over 10 years while CSIQ stands at 380.82%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-15.41%
Negative 5Y equity/share growth while CSIQ is at 68.28%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
5052.45%
3Y equity/share CAGR above 1.5x CSIQ's 29.80%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
11.77%
AR growth well above CSIQ's 5.42%. Michael Burry fears inflated revenue or higher default risk in the near future.
20.53%
Inventory growth well above CSIQ's 9.67%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-16.16%
Negative asset growth while CSIQ invests at 8.77%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-12.72%
We have a declining book value while CSIQ shows 5.50%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-40.99%
We’re deleveraging while CSIQ stands at 13.51%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
30.34%
We increase R&D while CSIQ cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
10.61%
We expand SG&A while CSIQ cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.